Volume 43, number S4: Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care
16th Nov 2006, 21:43 GMT
Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the “value for money” of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.
Latest news from Clin Infect Dis Latest Issue:
- Volume 43, number S4: Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
- Volume 43, number S4: Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
- Volume 43, number S4: The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
- Volume 43, number S4: A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
- Volume 43, number S4: Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States
- Volume 43, number S4: Buprenorphine Use: The International Experience
- Volume 43, number S4: Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
- Volume 43, number S4: Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop